F 16915 |
Catalog No.GC34039
One-Click Copy Product Info
|
F 16915, a Docosahexaenoic Acid derivative, is a potent pro-drug of DHA.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 92510-91-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
F 16915 is a docosahexaenoic acid derivative which can prevent heart failure-induced atrial fibrillation.
F 16915 is a docosahexaenoic acid derivative which can prevent heart failure-induced atrial fibrillation. Time-dependent changes in blood concentrations of total docosahexaenoic acid (DHA) and nicotinyl alcohol are followed after a single oral administration of F 16915 (300 mg/kg) to male rats. Treatment with F 16915 has no significant effect on body weight: 27.7±2.9 kg and 28.1±1.0 kg before surgery versus 29.2±3.4 kg and 28.8±1.7 kg after in the 1 and 5 g/day groups, respectively. F 16915 administered at 5 g/day for 4 weeks significantly reduces the mean duration of Atrial fibrillation (AF) induced by burst pacing but has no significant effect at 1 g/day. The duration of AF is significantly reduced from 989±111 s in the placebo group to 79±59 s in the presence of F 16915 at 5 g/day. Treatment of 2 months with 100 mg/kg F 16915 also significantly reduces the infarct size[1].
[1]. Le Grand B, et al. F 16915 prevents heart failure-induced atrial fibrillation: a promising new drug as upstream therapy. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):667-77.
Animal experiment: | Male Sprague-Dawley rats weighing 220 to 300 g are used in this study. The rats are anesthetized using isoflurane 3% on O2. Then, the animals are intubated and ventilated at 60 respirations/min (2.5 mL/respiration) while anesthesia is maintained. A left thoracotomy is performed, and a silk suture is placed around the left coronary artery ~1 mm from its origin. The treatment starts just after the surgery. A single administration of 100 mg/kg F 16915 or vehicle (olive oil) is daily administrated orally by force-feeding[1]. |
References: [1]. Le Grand B, et al. F 16915 prevents heart failure-induced atrial fibrillation: a promising new drug as upstream therapy. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):667-77. | |
| Cas No. | 92510-91-3 | SDF | |
| Canonical SMILES | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(OCC1=CC=CN=C1)=O | ||
| Formula | C28H37NO2 | M.Wt | 419.6 |
| Solubility | DMSO : ≥ 100 mg/mL (238.32 mM) | Storage | -20°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3832 mL | 11.9161 mL | 23.8322 mL |
| 5 mM | 476.6 μL | 2.3832 mL | 4.7664 mL |
| 10 mM | 238.3 μL | 1.1916 mL | 2.3832 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)